TADAQOR Trademark

Trademark Overview

On Thursday, June 16, 2022, a trademark application was filed for TADAQOR with the United States Patent and Trademark Office. The USPTO has given the TADAQOR trademark a serial number of 97461837. The federal status of this trademark filing is ABANDONED - NO STATEMENT OF USE FILED as of Monday, January 8, 2024. This trademark is owned by TEVA PHARMACEUTICALS USA, Inc.. The TADAQOR trademark is filed in the Pharmaceutical Products category with the following description:

Pharmaceutical preparations for the prevention and treatment of autoimmune diseases and disorders, blood and circulatory diseases and disorders, cardiovascular diseases and disorders, digestive diseases and disorders, endocrine diseases and disorders, immunological diseases and disorders, dermatological diseases and disorders (skin), musculoskeletal diseases and disorders, central and peripheral nervous system diseases and disorders, metabolic diseases and disorders, renal diseases and disorders, respiratory diseases and disorders, urogenital diseases and disorders, and urinary diseases and disorders, pharmaceutical preparations for use in the treatment of cancer, drug dependence, fertility disorders, hormone replacement, infectious diseases, inflammatory conditions, menopause, ophthalmic disorders and diseases, pain, and psychological disorders; pharmaceutical preparations for use in smoking cessation; contraceptive preparations
tadaqor

General Information

Serial Number97461837
Word MarkTADAQOR
Filing DateThursday, June 16, 2022
Status606 - ABANDONED - NO STATEMENT OF USE FILED
Status DateMonday, January 8, 2024
Registration Number0000000
Registration DateNOT AVAILABLE
Mark Drawing4000 - Illustration: Drawing with word(s) / letter(s) / number(s) in Block form
Published for Opposition DateTuesday, April 11, 2023

Trademark Statements

Goods and ServicesPharmaceutical preparations for the prevention and treatment of autoimmune diseases and disorders, blood and circulatory diseases and disorders, cardiovascular diseases and disorders, digestive diseases and disorders, endocrine diseases and disorders, immunological diseases and disorders, dermatological diseases and disorders (skin), musculoskeletal diseases and disorders, central and peripheral nervous system diseases and disorders, metabolic diseases and disorders, renal diseases and disorders, respiratory diseases and disorders, urogenital diseases and disorders, and urinary diseases and disorders, pharmaceutical preparations for use in the treatment of cancer, drug dependence, fertility disorders, hormone replacement, infectious diseases, inflammatory conditions, menopause, ophthalmic disorders and diseases, pain, and psychological disorders; pharmaceutical preparations for use in smoking cessation; contraceptive preparations

Classification Information

International Class005 - Pharmaceutical and veterinary preparations; sanitary preparations for medical purposes; dietetic substances adapted for medical use, food for babies; plasters, materials for dressings; material for stopping teeth, dental wax; disinfectants; preparations for destroying vermin; fungicides, herbicides.
US Class Codes005, 006, 018, 044, 046, 051, 052
Class Status Code6 - Active
Class Status DateTuesday, July 5, 2022
Primary Code005
First Use Anywhere DateNOT AVAILABLE
First Use In Commerce DateNOT AVAILABLE

Trademark Owner History

Party NameTEVA PHARMACEUTICALS USA, Inc.
Party Type20 - Owner at Publication
Legal Entity Type03 - Corporation
AddressParsippany, NJ 07054
Party NameTEVA PHARMACEUTICALS USA, Inc.
Party Type10 - Original Applicant
Legal Entity Type03 - Corporation
AddressParsippany, NJ 07054

Trademark Events

Event DateEvent Description
Monday, January 8, 2024ABANDONMENT NOTICE E-MAILED - NO USE STATEMENT FILED
Monday, January 8, 2024ABANDONMENT - NO USE STATEMENT FILED
Tuesday, June 6, 2023NOA E-MAILED - SOU REQUIRED FROM APPLICANT
Tuesday, April 11, 2023OFFICIAL GAZETTE PUBLICATION CONFIRMATION E-MAILED
Tuesday, April 11, 2023PUBLISHED FOR OPPOSITION
Wednesday, March 22, 2023NOTIFICATION OF NOTICE OF PUBLICATION E-MAILED
Friday, March 3, 2023APPROVED FOR PUB - PRINCIPAL REGISTER
Tuesday, February 28, 2023ASSIGNED TO EXAMINER
Tuesday, July 5, 2022NEW APPLICATION OFFICE SUPPLIED DATA ENTERED
Monday, June 20, 2022NEW APPLICATION ENTERED

Related Keywords

tadaqor disorders diseases preparations pharmaceutical treatment fertility hormone replacement dependence infectious